Evaluation of the effects of celecoxib on mouse lymphoma cells (EL4)
Subject Areas :
Journal of Comparative Pathobiology
Leyla Emami
1
,
Sh Safi
2
,
Farhad Zaker
3
1 - Doctor of Veterinary Medicine, Faculty of Specialized Veterinary Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran
2 - .Department of Pathology and Clinical Pathology, Faculty of Specialized Veterinary Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran.
3 - Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
Received: 2019-06-08
Accepted : 2019-06-08
Published : 2019-05-22
Keywords:
Celecoxib,
Apoptosis,
EL4 cell line,
Mouse,
Lymphoma,
Abstract :
Lymphoma is one of the most common tumors in most species of the mouse. On the other hand, biologic, histopathologic and epidemiological characteristics of mouse lymphoma are similar to lymphoma in humans. Hence, tumor lymphoma in mice can be a suitable model for the biological study of human cancers. The objective of the present study was to evaluate the apoptotic and cytotoxic effects of celecoxib on mouse lymphoma tumor cells (EL4) using Annexin/PI and MTT assays. The results of MTT showed a dose and time-dependent inhibition of EL4 cells by celecoxib and 50% inhibition of cell survival at 20 μm of celecoxib. In addition, the percentage of cells with apoptosis increased after 48 hours exposure to IC50 concentration (50% survival of the exposed cells) of celecoxib. Based on the obtained results, it seems that celecoxib can be used as an adjunct therapy along with other compounds used to treat lymphoma in mice and probably in human medicine.
References:
_||_
Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB., et al. ( 2003): Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhance the response to preoperative paclitaxel and carboplatin in early- stage non-small-cell lung cancer. J. Clin. Oncol. 21(14): 2645-2650.
Anderson WF, Umar A, Viner JL, Hawk ET. (2002): The role of cyclooxygenase inhibitors in cancer prevention. Curr. Pharm. Des. 8(12):1035-1062.
Arunasree KM, Roy KR, Anilkumar K, Aparna A, Reddy GV, Reddanna P. (2008): Imatinib-resistant K562 cells are more sensitive to cecloxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk. Res. 32(6): 855-864.
Awara WM, El-Sisi AE, El-Sayad ME, Goda AE. (2004): The potential role of cyclooxygenase-2 inhibitors in the treartment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin? Pharmacol. Res. 50(5):487-498.
Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. (2005): Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res.7(4): R422-435.
Bocca C, Bozzo F, Bassignana A, Miglietta A. (2011): Antiproliferative eefects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol. Cell. Biochem. 350(1-2): 59-70.
De Groot DJ, de Vries EG, Groen HJ, de Jong S. (2007): Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit. Rev. Oncol. Hematol. 61(1): 52-69.
Ding H, Han C, Zhu J, Chen CS, D'Ambrosio SM. (2005): Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int. J. Cancer. 113(5): 803-810.
Dhawan D, Jeffreys AB, Zheng R, Stewart JC, Knapp DW. (2008): Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol. Cancer Ther. 7(4): 897-904.
10.Galloet AS, Travert M, Bepoldin LB, Trate K, Lamy T, Guilloton F, Pangault C, Laugendre SC, guillaudeux T.( 2014): COX-2 independent effects of celecoxib sensitize Lymphoma B cells to TRAIL-mediated apoptosis. Clin. Cancer Res. 20 (10): 2663-2673.
Grösch S, Maier TJ, Schiffmann S, Geisslinger G. (2006): Cyclooxygenase-2 (COX-2)–independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 98(11):736-747.
Kundu N, Smyth MJ, Samsel L, Fulton AM. (2002): Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res. Treat. 76(1): 57-64.
Nakamura M, Takahashi T, Matsui H, Takahashi S, Murayama SY, Suzuki H, Tsuchimoto K. (2014): New pharmaceutical treatment of gastric MALT lymphoma : anti-angiogenesis treatment using VEGF receptor antibodies and cecloxib. Curr. Pharm. Des. 20(7): 1097-1103.
Sovak M.A, Arsura M, Zanieski G, Kavanagh KT, Sonenshein GE. (1999): The inhibitory effects of transforming growth factor beta1 on breast cancer cell proliferation are mediated through regulation of aberrant nuclear factor-kappaB/Rel expression. Cell growth & differentiation: Cell Growth Differ. 10(8): 537-544.
Tegeder I, Pfeilschifter J, Geisslinger G. (2001): Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15(12): 2057-2072.
Ward JM. (2006): Lymphomas and leukemias in mice. Comparative Medicine Branch, National institute of Allergy and Infectious diseases, NIH. USA. 57(5-6): 377-381.
Waskewich, C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. (2002): Celecoxib exhibits the greatest potency amongst cyclooxygenase( COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 62(7): 2029-2033.
Zatelli MC, Luchin A, Tagliati F, Leoni S, Piccin D, Bondanelli M., et al. (2007): Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr. Relat. Cancer. 14(4): 1029-1038.
Zhang H, Ye Y, Bai Z, Wang S. (2008): The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1/Notch1 pathway. Dig. Dis. Sci. 53(8):2195-2203.